Antje Stolzenburg1, Katharina Lückerath1,2, Samuel Samnick1, Martin Speer1, Katharina Kneer3, Jan-Stefan Schmid1, Götz Ulrich Grigoleit4, Susanne Hofmann5,6, Ambros J Beer3, Donald Bunjes5, Stefan Knop4, Andreas K Buck1, Hermann Einsele4, Constantin Lapa7. 1. Department of Nuclear Medicine, University Hospital Würzburg, Medical Center, Würzburg, Germany. 2. Department of Molecular & Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, USA. 3. Department of Nuclear Medicine, University of Ulm, Medical Center, Ulm, Germany. 4. Department of Internal Medicine II, Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany. 5. Department of Internal Medicine III, Hematology and Oncology, University of Ulm, Medical Center, Ulm, Germany. 6. Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. 7. Department of Nuclear Medicine, University Hospital Würzburg, Medical Center, Würzburg, Germany. lapa_C@ukw.de.
Abstract
PURPOSE: Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F-2'-deoxy-2'-fluorodeoxyglucose ([18F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT). METHODS: In this retrospective analysis, we evaluated [18F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT. All scans were qualitatively and semi-quantitatively assessed for the presence of active disease. Serological response was recorded according to International Myeloma Working Group (IMWG) criteria. Progression-free (PFS) and overall survival (OS) were correlated with different PET/CT-derived parameters, such as presence, number and maximum standardized uptake value (SUVmax) of focal myeloma lesions. The impact of extramedullary disease on patient outcome was also assessed. RESULTS: PET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUVmax > 6.5) revealed a significantly shortened survival compared to patients with a lower SUVmax (<6.5) (OS, 5.0 ± 1.1 m vs. not reached - longest 122.0 m; p < 0.001). Moreover, our data prove that a higher number (>3) of focal lesions (pre-HCT: both PFS and OS: p < 0.001; post-HCT PFS: p < 0.001, OS: p = 0.139) as well as the presence of extramedullary disease serve as adverse prognostic factors prior to and after allo-HCT. At response assessment after allo-HCT, [18F]FDG-PET/CT had a complementary value in prognostication in addition to IMWG criteria alone. CONCLUSION: [18F]FDG-PET/CT before and shortly after allogeneic HCT is a powerful predictor for progression-free and overall survival in MM patients.
PURPOSE: Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F-2'-deoxy-2'-fluorodeoxyglucose ([18F]FDG) in MMpatients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT). METHODS: In this retrospective analysis, we evaluated [18F]FDG-PET/CT-scans of 45 heavily pre-treated MMpatients before and 27 patients after scheduled allo-HCT. All scans were qualitatively and semi-quantitatively assessed for the presence of active disease. Serological response was recorded according to International Myeloma Working Group (IMWG) criteria. Progression-free (PFS) and overall survival (OS) were correlated with different PET/CT-derived parameters, such as presence, number and maximum standardized uptake value (SUVmax) of focal myeloma lesions. The impact of extramedullary disease on patient outcome was also assessed. RESULTS: PET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUVmax > 6.5) revealed a significantly shortened survival compared to patients with a lower SUVmax (<6.5) (OS, 5.0 ± 1.1 m vs. not reached - longest 122.0 m; p < 0.001). Moreover, our data prove that a higher number (>3) of focal lesions (pre-HCT: both PFS and OS: p < 0.001; post-HCT PFS: p < 0.001, OS: p = 0.139) as well as the presence of extramedullary disease serve as adverse prognostic factors prior to and after allo-HCT. At response assessment after allo-HCT, [18F]FDG-PET/CT had a complementary value in prognostication in addition to IMWG criteria alone. CONCLUSION: [18F]FDG-PET/CT before and shortly after allogeneic HCT is a powerful predictor for progression-free and overall survival in MMpatients.
Authors: M Sobh; M Michallet; G Gahrton; S Iacobelli; A van Biezen; S Schönland; E Petersen; N Schaap; F Bonifazi; L Volin; E Meijer; D Niederwieser; J El Cheikh; R Tabrizi; N Fegeux; J Finke; D Bunjes; J Cornelissen; H Einsele; B Bruno; M Potter; R Fanin; M Mohty; L Garderet; N Kröger Journal: Leukemia Date: 2016-04-27 Impact factor: 11.528
Authors: Constantin Lapa; Maria J Garcia-Velloso; Katharina Lückerath; Samuel Samnick; Martin Schreder; Paula Rodriguez Otero; Jan-Stefan Schmid; Ken Herrmann; Stefan Knop; Andreas K Buck; Hermann Einsele; Jesus San-Miguel; Klaus Martin Kortüm Journal: Theranostics Date: 2017-07-23 Impact factor: 11.556
Authors: Maria I Morales-Lozano; Oliver Viering; Samuel Samnick; Paula Rodriguez-Otero; Andreas K Buck; Maria Marcos-Jubilar; Leo Rasche; Elena Prieto; K Martin Kortüm; Jesus San-Miguel; Maria J Garcia-Velloso; Constantin Lapa Journal: Cancers (Basel) Date: 2020-04-23 Impact factor: 6.639
Authors: Sabrina Kraus; Philipp Klassen; Malte Kircher; Alexander Dierks; Stefan Habringer; Alexander Gäble; Klaus Martin Kortüm; Niels Weinhold; Valëza Ademaj-Kospiri; Rudolf A Werner; Andreas Schirbel; Andreas K Buck; Peter Herhaus; Hans-Jürgen Wester; Andreas Rosenwald; Wolfgang A Weber; Hermann Einsele; Ulrich Keller; Leo Rasche; Constantin Lapa Journal: Theranostics Date: 2022-08-08 Impact factor: 11.600